ProfileGDS5678 / 1415947_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 98% 97% 97% 98% 97% 98% 98% 97% 97% 96% 97% 97% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.6794598
GSM967853U87-EV human glioblastoma xenograft - Control 29.6882697
GSM967854U87-EV human glioblastoma xenograft - Control 39.6197297
GSM967855U87-EV human glioblastoma xenograft - Control 49.9613598
GSM967856U87-EV human glioblastoma xenograft - Control 59.5777597
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 19.6337398
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.4978398
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.4317997
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.355297
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.0688996
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.3872797
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.4826997
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.237797
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.3315897